GB202210965D0 - Novel dosages - Google Patents

Novel dosages

Info

Publication number
GB202210965D0
GB202210965D0 GBGB2210965.6A GB202210965A GB202210965D0 GB 202210965 D0 GB202210965 D0 GB 202210965D0 GB 202210965 A GB202210965 A GB 202210965A GB 202210965 D0 GB202210965 D0 GB 202210965D0
Authority
GB
United Kingdom
Prior art keywords
dosages
novel
novel dosages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2210965.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Priority to GBGB2210965.6A priority Critical patent/GB202210965D0/en
Publication of GB202210965D0 publication Critical patent/GB202210965D0/en
Priority to PCT/EP2023/070640 priority patent/WO2024023118A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
GBGB2210965.6A 2022-07-27 2022-07-27 Novel dosages Ceased GB202210965D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2210965.6A GB202210965D0 (en) 2022-07-27 2022-07-27 Novel dosages
PCT/EP2023/070640 WO2024023118A1 (en) 2022-07-27 2023-07-25 Novel dosages of anti-cd137 antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2210965.6A GB202210965D0 (en) 2022-07-27 2022-07-27 Novel dosages

Publications (1)

Publication Number Publication Date
GB202210965D0 true GB202210965D0 (en) 2022-09-07

Family

ID=84540499

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2210965.6A Ceased GB202210965D0 (en) 2022-07-27 2022-07-27 Novel dosages

Country Status (2)

Country Link
GB (1) GB202210965D0 (en)
WO (1) WO2024023118A1 (en)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (en) 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CN1671416B (en) 2001-07-12 2013-01-02 杰斐逊·富特 Super humanized antibodies
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
AU2021271971A1 (en) * 2020-05-13 2023-02-02 Adagene Ag Compositions and methods for treating cancer
CA3202416A1 (en) * 2020-12-16 2022-06-23 Pieter Fokko VAN LOO Multispecific antibodies for the treatment of cancer

Also Published As

Publication number Publication date
WO2024023118A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
CA216403S (en) Hoodie
GB202210957D0 (en) Novel dosages
GB202210965D0 (en) Novel dosages
CA217437S (en) Footwarmer
CA215379S (en) E-track
CA214906S (en) Multi-cooker
CA215434S (en) Thermo-hygrometer
CA215433S (en) Thermo-hygrometer
CA210085S (en) Muddler
GB202208027D0 (en) Novel polypeptieds
GB202201813D0 (en) Case
GB202201810D0 (en) Case
GB202219539D0 (en) Construct
GB202209834D0 (en) Ten
GB202209842D0 (en) Four
GB202211746D0 (en) Gozakacchongozaso-hteiquezonematamatamatajuhjikivaizone
GB202211719D0 (en) Kaijitsudonmai
GB202211668D0 (en) Exwg-olayemi-c2022jul1-f2022jul27-tbs
GB202211339D0 (en) Kanjitsuhajuhjikivai
GB202211340D0 (en) Kanjitsuhajuhjikivai
GB202211182D0 (en) Bead-hashing
GB202210960D0 (en) Tees-Lashin
GB202211010D0 (en) Akorker
GB202210274D0 (en) Withim
GB202209344D0 (en) Hdroponics

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)